

- TO: Primary care providers, infectious disease, laboratories, infection control, and public health
- FROMThomas J. Safranek, M.D.<br/>State EpidemiologistJeff Hamik<br/>Vector-Borne Disease Epidemiologist<br/>402-471-2937 PHONE<br/>402-471-3601 FAXJeff Hamik<br/>402-471-1374 PHONE<br/>402-471-3601 FAX

RE: COLLECTIONS OF ESTABLISHED POPULATIONS OF *IXODES SCAPULARIS* (BLACK-LEGGED TICK) IN NEBRASKA

DATE: <u>June 25, 2019</u>

This report addresses the first confirmation of established (per CDC criteria) *Ixodes scapularis* (black-legged tick or deer tick) populations in Nebraska (Douglas, Sarpy, and Saunders counties).

## Key messages for Nebraska clinicians:

For the past 30 years the Office of Epidemiology at Nebraska Department of Health and Human Services has carefully monitored the ecology of Nebraska's tick species implicated in human disease, and any patients with tick-borne diseases reported to public health. Until recently, we have not identified established populations of the *Ixodes scapularis* (black-legged) tick, the known vector of Lyme disease, nor have we identified patients with confirmed Lyme disease (meeting nationally accepted criteria) with plausible local acquisition in Nebraska.

While state and Federal support for tick surveillance field work is limited, in the past year we broadened tick surveillance efforts through a partnership with entomologists at Nebraska Department of Agriculture and the University of Nebraska-Lincoln. As part of this collaboration, in early June, a Nebraska Department of Agriculture entomologist identified for the first time an established population of *I. scapularis* ticks. On June 1, 2019 five larvae, two nymphs, and one adult male *I. scapularis* were collected at a site in Sarpy County. On June 7, a nymph was collected at a site in Douglas County where two adult deer ticks were collected during December 2018. Then on June 8, ten larvae and two nymphs were collected at a site in Saunders County. These collections meet CDC's criteria for *I. scapularis* established populations. CDC's criteria are based on collecting either  $\geq 6$  individuals or more than one life stage from a specific location in a 12-month period.

Laboratory studies are currently ongoing to determine if any of the collected ticks carry any of the pathogens listed below. Pending this, the local human health risk is unknown, but clearly of increased concern.

*I. scapularis* is the vector of *Borrelia burgdorferi*, the causative agent of Lyme disease; *Anaplasma phagocytophilum*, the causative agent of human granulocytic anaplasmosis; and *Babesia microti*, the causative agent of human babesiosis. Additionally, this tick is also the vector of Powassan virus. At present, human infections with this virus are rare and have only been identified in the New England and mid-Atlantic regions of the U.S.

These findings warrant increased vigilance for infections transmitted by *I. scapularis* on the part of Nebraska health care providers. Healthcare providers need to know and follow recommended testing guidelines to establish the diagnosis of any of these agents, particularly with regards to two-step testing for suspected Lyme disease at a reputable laboratory. Such testing is readily available through commercial clinical reference laboratories (e.g. ARUP, Mayo, Quest, etc.).

Plans for additional tick surveillance are being made. Additional information will be published as it becomes available.

Previous information regarding clinical symptoms, testing and treatment were sent out in earlier health alerts and can be found here:

Tick-Borne Diseases in Nebraska (http://dhhs.ne.gov/han%20Documents/ADVISORY031919.pdf)

Lyme Disease in Nebraska (http://dhhs.ne.gov/han%20Documents/ADVISORY042319.pdf)

## For more information please visit:

CDC Anaplasmosis Page: https://www.cdc.gov/anaplasmosis/index.html

CDC Lyme Disease Page: <u>https://www.cdc.gov/lyme/</u>

CDC Tickborne Diseases of the US: A Reference Manual for Health Care Providers, Fourth Edition (2017): <u>https://www.cdc.gov/lyme/resources/TickborneDiseases.pdf</u>

## **References:**

Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP; Ad Hoc International Lyme Disease Group, Agger WA, Artsob H, Auwaerter P, Dumler JS, Bakken JS, Bockenstedt LK, Green J, Dattwyler RJ, Munoz J, Nadelman RB, Schwartz I, Draper T, McSweegan E, Halperin JJ, Klempner MS, Krause PJ, Mead P, Morshed M, Porwancher R, Radolf JD, Smith RP Jr, Sood S, Weinstein A, Wong SJ, Zemel L. A critical appraisal of "chronic Lyme disease". N Engl J Med. 2007 Oct 4; 357(14):1422-30.

Hu LT. Lyme Disease. Ann Intern Med. 2016 Nov 1; 165(9):677.

Marques A. Chronic Lyme disease: An appraisal. Infect Dis Clin North Am. 2008 Jun 1; 22(2):341-60.

Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: A review. JAMA. 2016 Apr 26; 315(16):1767-77.